Mastectomy, custom breast prosthesis, mixed methodology, cancer rehabilitation, quality of life URL http://www.current-oncology.com/index. php/oncology/article/view/851/ E-JOURNAL LINKED ABSTRACT Background: Of all mastectomy patients, 90% will use an external prosthesis where the standard of care uses a stock prosthesis that is purchased "off the shelf." Our objectives were to determine patient demand for and perceived value of a custom breast prosthesis. The information obtained will influence future research and program direction.
Results: All the women had had previous experiences with a conventional prosthesis, and they reported that wearing a custom prosthesis was more satisfying for them. They reported comfort and ease in wearing it, coupled with a sense of feeling less like a victim. Comparison of the qlq and patient satisfaction scores BARH et al. Full text of these articles appears at www.current-oncology.com *With the increasing national and international popularity and exposure of Current Oncology, the queue of excellent submissions continues to lengthen. After substantial consideration, the journal's management has determined that the best way to manage this abundance is to move to a "hybrid" of combined print and electronic publication, with every e-manuscript being supported by a full print abstract and key words, and of course, indexing in PubMed for international recognition.
e-MAnuSCriPt ArtiCle SuMMArieS* showed no significant difference between the women wearing the conventional prosthesis and those wearing the custom prosthesis.
Conclusions:
The willingness of women to pay for a prosthesis and the qualitative results from the present study demonstrate that there is demand for a custom approach to treatment. However, if a mixed-methods approach had not been applied during this initial exploration of women's experiences with custom breast prostheses, the essence of the perceived value of the custom prosthesis would have been lost. Quantitative measures suggest that there is no difference between custom and conventional breast prostheses, but the qualitative data captured in the study provide a sense of aspects of care that a standardized outcome measure cannot capture. Further research with a larger sample size is needed to determine if real differences from a quantitative perspective are possible. Suggestions for improvements in the device and in program operations were gathered and will influence the future development and implementation of a breast prosthesis service, but financial assistance will most likely be needed to make such a service universally accessible. 
E-JOURNAL LINKED ABSTRACT
Background: Non-small-cell lung cancer (nsclc) tumours with activating mutations of the epidermal growth factor receptor (efgr) tyrosine kinase are highly sensitized to the effects of oral tyrosine kinase inhibitors such as gefitinib and erlotinib, suggesting the possibility of targeted treatment of nsclc based on EFGR mutation status. However, no standardized method exists for assessing the EGFR mutation status of tumours. Also, it is not known if available methods are feasible for routine screening. To address that question, we conducted a validation study of methods used at molecular laboratories in five specialized Canadian cancer centres for detecting EGFR mutations in exons 19 and 21.
Methods:
The screening methods were first optimized using cell lines harbouring the mutations in question. A validation phase using anonymized patient samples followed.
Results:
The methods used at the sites were highly specific and sensitive in detecting both mutations in cell-line dna (specificity of 100% and sensitivity of at least 1% across all centres). In the validation phase, we observed excellent concordance between the laboratories for detecting mutations in the patient samples. Concordant results were obtained in 26 of 30 samples (approximately 87%). In general, the samples for which results were discordant were also less optimal, containing small amounts of tumour.
Conclusions:
Our results suggest that currently available methods are capable of reliably detecting exon 19 and exon 21 mutations of EFGR in tumour samples (provided that sufficient tumour material is available) and that routine screening for those mutations is feasible in clinical practice. 
Phase ii trial of a Metronomic Schedule of Docetaxel and Capecitabine with Concurrent Celecoxib in Patients with

E-JOURNAL LINKED ABSTRACT
Background: Preclinical studies using tumour models have shown that the therapeutic index of chemotherapeutic drugs can be increased if these drugs are administered more frequently at minimally toxic doses. This approach, called "metronomic dosing," appears to achieve anticancer activity by targeting dividing endothelial cells participating in tumour angiogenesis. A phase ii trial was conducted to determine whether this effect could be reproduced in patients with advanced breast cancer and with prior exposure to an anthracycline. Participants were given low once-daily doses of capecitabine and weekly infusions of docetaxel in uninterrupted fashion while on study. These agents were chosen because experimental evidence has indicated that concurrent administration can produce therapeutic synergy. In addition, in an effort to improve outcome measures, patients received daily oral celecoxib because this cyclo-oxygenase-2 inhibitor may also possess antiangiogenic activity.
Methods:
Patients received weekly docetaxel at a starting dose of 15 mg/m 2 , once-daily oral capecitabine 1250 mg/m 2 , and twice-daily oral celecoxib 200 mg. Treatment was given continuously until disease progression or unacceptable toxicity. In the absence of neutropenia, the docetaxel dose was escalated after 4 and 8 weeks of therapy to a maximum of 25 mg/m 2 . The primary endpoint was clinical benefit (percentage of patients experiencing either an objective response according to the Response Evaluation Criteria in Solid Tumors or achieving disease stabilization for 6 months or more). Secondary endpoints included time to disease progression, overall survival, and toxicity. The level of thymidine phosphorylase expression in the peripheral white blood cells of patients was measured before and during treatment to determine the effect of therapy on this capecitabineactivating enzyme.
Results:
The study enrolled 47 patients, among whom 38 (81%) completed treatment to a disease assessment endpoint. No complete responses were achieved, but 13 patients (34%) experienced a partial response, and an additional 3 (8%) experienced stable disease for at least 6 months. The clinical benefit rate was therefore 42% (95% confidence interval: 27% to 57%). The median time to disease progression for all evaluable patients was 3.6 months (range: 0.9 to 21.7 months). The most common non-hematologic toxicities were diarrhea, plantar-palmar erythrodysesthesia, fatigue, mucositis, and vomiting.
Conclusions:
The present study demonstrates that metronomic docetaxel-capecitabine chemotherapy
E-JOURNAL LINKED ABSTRACT
Context: Although initial conceptualizations of distress focused primarily on symptoms of anxiety and depression, recent models expand that understanding by viewing distress as a result of any one or a combination of psychosocial, practical, and physical problems. Studies in patients with advanced cancer have focused to a greater extent on psychological and symptom distress to the exclusion of practical and other psychosocial problems.
Objectives: In the current study, we sought to prospectively characterize distress and related physical, psychological, and other problems in a cohort of ambulatory patients referred to a tertiary symptom control clinic, comparing them with a group of cancer patients attending the same cancer centre but not referred to the symptom control clinic, but matched for several important variables.
Methods: Clinic and comparison-group patients were invited to complete screening instruments designed to assess distress, pain, fatigue, anxiety, depression, and practical and psychosocial problems.
Results:
The screening measures were completed by 46 patients attending the symptom control clinic (77% of those eligible) and by 46 comparison-group patients. Clinic patients reported distress (78.3%), pain (93.5%), and fatigue (93.5%) more frequently than did patients in the comparison group. Clinic patients also more frequently reported multiple severe concurrent symptoms, with 87% scoring 7 or higher on at least one of the pain, fatigue, and distress scales, and with 30.4% scoring 7 or higher on all three. The most common problem areas in clinic patients were feeling a burden to others, having trouble talking with friends and family, and experiencing spirituality and sleep difficulties.
Conclusions:
Compared with a matched group of patients who did not attend a symptom control clinic, clinic patients showed higher levels of multiple concurrent symptoms and psychosocial problems. We recommend that, rather than take an approach to symptom management that targets each symptom individually, co-occurring symptoms should be identified so that patients can be provided with additional multidisciplinary resources in a timely and efficient manner. The results of the present study attest to the legitimacy of calls for ambulatory cancer programs to more effectively integrate and coordinate services from initial diagnosis through to survivorship or palliation; to include comprehensive patient assessment and an interdisciplinary approach as the standard of care in all clinics; and to conduct more research into how symptoms and other issues faced by patients and their families tend to evolve during the course of an illness. 
What is the
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Esophageal cancer, palliation, stents, radiation therapy URL http://www.current-oncology.com/index. php/oncology/article/view/892/ E-JOURNAL LINKED ABSTRACT Background: The palliation of dysphagia in metastatic esophageal cancer remains a challenge, and the optimal approach for this difficult clinical scenario is not clear. We therefore sought to define and determine the efficacy of various treatment options used at our institution for this condition by examining the potential advantages of a combined-modality treatment over those of stenting or radiotherapy alone.
